Glaxosmithkline
Clinical trials sponsored by Glaxosmithkline, explained in plain language.
A global pharmaceutical company developing vaccines and specialty medicines.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a single drug replace surgery for rectal cancer?
⭐️ CURE ⭐️ Not yet recruitingThis study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ CURE ⭐️
Last updated Aug 05, 2026 00:00 UTC
-
Shigella vaccine immunity checked years later in african kids
⭐️ VACCINE ⭐️ Not yet recruitingThis study follows up on African children who received an experimental Shigella vaccine in earlier studies. Researchers will take blood samples 1, 2, and 3 years after the last vaccine dose to see how long the immune protection lasts. No new vaccines are given in this study. The …
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new biologic calm the immune attack in ulcerative colitis?
Disease control Not yet recruitingThis early-stage trial is testing whether a drug called aletekitug is safe and tolerable for people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The drug works by blocking a protein called IL-18, which may play a role in the inflammation that …
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new biologic tame ulcerative colitis?
Disease control Not yet recruitingThis early trial is testing an experimental biologic drug called aletekitug in adults with moderate to severe ulcerative colitis. The main goal is to see if the drug is safe and tolerable when given repeatedly. Researchers will monitor side effects and changes in lab tests, vital…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a simple injection replace an IV for this myeloma drug?
Disease control Not yet recruitingThis trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a vaccine protect your heart? study tests shingles and RSV shots against artery plaque
Disease control Not yet recruitingThis study investigates whether two common vaccines—the shingles vaccine (RZV) and an RSV vaccine (RSVPreF3)—can slow the buildup of fatty plaque in the coronary arteries. The trial enrolls adults aged 50 and older who are at risk for cardiovascular events. Participants receive e…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pneumonia vaccine put to the test in babies
Disease control Not yet recruitingThis early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it may cause. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new v…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug duo aims to outperform chemo in ovarian cancer
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a single biologic replace steroid sprays for nasal polyps?
Disease control Not yet recruitingThis study tests whether the biologic drug depemokimab, given as a shot, can shrink nasal polyps in Japanese adults with chronic sinusitis and nasal polyps who have not been helped by standard treatments. Participants receive depemokimab without using steroid nasal sprays. The ma…
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug velzatinib tested for Hard-to-Treat stomach and intestinal tumors
Disease control Not yet recruitingThis phase 2 trial tests the drug velzatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to or cannot tolerate several standard treatments. The study aims to see if velzatinib can shrink or control the tumors and how safe it is. Par…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New malaria pill shows promise in early trial
Disease control Not yet recruitingThis phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work …
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for GIST: velzatinib takes on imatinib in major trial
Disease control Not yet recruitingThis phase 3 trial compares a new drug, velzatinib, to the standard drug imatinib in 800 people with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The goal is to see if velzatinib can delay tumor growth better than imatinib. Par…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New asthma shot could help kids breathe easier
Disease control Not yet recruitingThis study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The go…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New dosing strategy aims to reduce eye side effects in myeloma treatment
Disease control Not yet recruitingThis phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for tough lymphoma: experimental drug GSK5926371 enters human trials
Disease control Not yet recruitingThis early-stage trial tests a new drug called GSK5926371 in about 49 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tame advanced uterine cancer
Disease control Not yet recruitingThis study tests the safety of the immunotherapy drug dostarlimab when given together with standard chemotherapy (carboplatin and paclitaxel) as a first treatment for adults in India with advanced or recurrent endometrial cancer. Participants receive the drug combination initiall…
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hope for rare disease: new drug trial for VEXAS syndrome begins
Disease control Not yet recruitingThis study tests a drug called momelotinib in 136 adults with VEXAS syndrome, a rare inflammatory disease caused by a genetic mutation. The goal is to see if the drug can reduce disease activity, with participants receiving either momelotinib or a placebo. This is a phase 2/3 tri…
Phase: PHASE2, PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a new Four-in-One vaccine match the gold standard for childhood protection?
Prevention Not yet recruitingThis study tests an investigational vaccine that combines protection against measles, mumps, rubella, and chickenpox (varicella) in a single shot. It will be given as a second dose to healthy children aged 4 to 6 years who have already received a first dose of a similar vaccine. …
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
New malaria antibody enters first human safety tests
Prevention Not yet recruitingThis early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe …
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New asthma inhaler ingredient put to the test
Symptom relief Not yet recruitingThis study checks if a new propellant (HFA-152a) in asthma inhalers is as safe as the current one (HFA-134a). About 110 adults with asthma will use both types of inhalers and be monitored for side effects. The goal is to make sure the new propellant is safe for everyday use.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Antibiotic levels in breast milk under the microscope
Knowledge-focused Not yet recruitingThis study measures how much of the antibiotic gepotidacin passes into breast milk after a single 3000 mg dose. Eight healthy lactating women will provide milk and blood samples over 72 hours. The goal is to understand drug exposure for nursing infants, which could guide future u…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
New study checks liver impact on myeloma drug combo
Knowledge-focused Not yet recruitingThis early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and saf…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New kidney disease drug candidate tested in healthy people for first time in asia
Knowledge-focused Not yet recruitingThis early-phase trial will test a single dose of the experimental drug GSK4771261 in 30 healthy adults of Chinese, Japanese, and White/European backgrounds. The main goal is to check safety, how the body processes the drug, and whether it causes an immune response. No treatment …
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New antibiotic gepotidacin tested in kids for first time
Knowledge-focused Not yet recruitingThis early-stage study will give a single dose of the experimental antibiotic gepotidacin to 20 hospitalized children aged 2 to 12 who are already receiving standard antibiotics for a bacterial infection or as a preventive measure. Researchers will measure how the drug moves thro…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC